AORT Artivion, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AORT Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$43.02
Analyst Target
$51.71
+20.2%
Upside
52W High
$48.25
52W Low
$21.97
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$2.04B
P/E
N/A
ROE
-2.5%
Profit margin
-2.2%
Debt/Equity
0.6
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
The company exhibits a weak fundamental health with a Piotroski F-Score of just 2/9, indicating significant operational and financial concerns. Despite strong revenue growth of 18.4% and impressive recent earnings surprises, the negative profit margin (-2.16%) and negative ROE (-2.46%) reflect persistent profitability issues. Valuation metrics are stretched, with a Forward P/E of 50.97 and Price/Book of 4.65, while insider selling worth $9.73M signals management's lack of confidence. Although balance sheet liquidity is strong (Current Ratio: 3.93), the absence of Altman Z-Score and weak earnings quality undermine long-term sustainability.
Key Strengths
Strong year-over-year revenue growth of 18.40%
High gross margin of 64.50%, indicating pricing power or cost efficiency
Exceptional recent earnings surprise history, averaging +43.53% over last four quarters
Strong liquidity position with Current Ratio of 3.93 and Quick Ratio of 1.99
Significant analyst target price of $51.71, implying 20.2% upside
Key Risks
Very low Piotroski F-Score of 2/9, signaling weak financial health
Negative net profit margin (-2.16%) and negative ROE (-2.46%), indicating unprofitability
Lack of Altman Z-Score raises uncertainty about solvency risk
Insiders have been aggressively selling, with $9.73M in sales and zero buys in last 6 months
High valuation despite losses: Forward P/E of 50.97 on negative earnings
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
25
65
50
20
0
AI Verdict
High-risk profile with unsustainable fundamentals despite growth and sentiment support
Key drivers: Low Piotroski F-Score (2/9), Negative profitability metrics, Aggressive insider selling, High forward valuation on unprofitable earnings, Strong revenue growth and analyst target support
Confidence
80%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Analyst target implies upside
Watchpoints
- Forward P/E of 50.97 is extremely high for an unprofitable company
- No Graham Number due to unprofitability
- Price/Book of 4.65 is elevated for sector
Future
65/100
Ref Growth rates
Positives
- Revenue growth of 18.40% YoY
- Strong earnings surprise trend
- Year-over-year EPS growth of +128.6%
Watchpoints
- Most recent Q/Q EPS growth down -33.3%
- Earnings volatility remains high
Past
50/100
Ref Historical trends
Positives
- History of beating earnings estimates (3 of last 4 quarters)
Watchpoints
- Erratic earnings performance with multiple negative quarters
- Large negative surprises in prior periods
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.60 is moderate
- Strong Current and Quick Ratios
Watchpoints
- Piotroski F-Score of 2/9 indicates severe financial weakness
- Negative ROE and negative net income
- No Altman Z-Score reported
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$43.02
Analyst Target
$51.71
Upside/Downside
+20.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AORT and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AORT
Artivion, Inc.
Primary
|
+72.4% | +236.1% | +40.5% | +37.0% | -8.2% | -0.8% |
|
ADPT
Adaptive Biotechnologies Corporation
Peer
|
-69.3% | +61.8% | +83.7% | +4.4% | -15.7% | -11.4% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
|
AHG
Akso Health Group
Peer
|
+24.4% | +547.7% | +88.2% | +30.8% | +77.3% | +85.2% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
50.97
PEG Ratio
N/A
P/B Ratio
4.65
P/S Ratio
4.82
EV/Revenue
5.27
EV/EBITDA
45.56
Market Cap
$2.04B
Profitability
Profit margins and return metrics
Profit Margin
-2.16%
Operating Margin
10.26%
Gross Margin
64.5%
ROE
-2.46%
ROA
1.95%
Growth
Revenue and earnings growth rates
Revenue Growth
+18.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.6
Moderate
Current Ratio
3.93
Strong
Quick Ratio
1.99
Excellent
Cash/Share
$1.55
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-23
$N/A
2025-11-06
$0.16
+5.3% surprise
2025-08-07
$0.24
+92.0% surprise
2025-05-05
$0.06
+33.3% surprise
Healthcare Sector Comparison
Comparing AORT against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-2.46%
This Stock
vs
-52.77%
Sector Avg
-95.3%
(Below Avg)
Profit Margin
-2.16%
This Stock
vs
-20.78%
Sector Avg
-89.6%
(Weaker)
Debt to Equity
0.6
This Stock
vs
6.16
Sector Avg
-90.3%
(Less Debt)
Revenue Growth
18.4%
This Stock
vs
137.39%
Sector Avg
-86.6%
(Slower)
Current Ratio
3.93
This Stock
vs
3.36
Sector Avg
+17.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AORT
Artivion, Inc.
|
BEARISH | $2.04B | - | -2.5% | -2.2% | $43.02 | |
|
ADPT
Adaptive Biotechnologies...
|
BEARISH | $2.03B | - | -27.8% | -21.5% | $13.17 | |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 | |
|
AHG
Akso Health Group
|
BEARISH | $2.14B | - | -68.3% | -% | $2.5 | |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | DAVIS JOHN E | Officer | Sale | 5,000 | $225,550 |
| 2025-12-08 | HORTON AMY D | Officer | Sale | 4,572 | $203,084 |
| 2025-12-03 | MACKIN JAMES PATRICK | Chief Executive Officer | Sale | 30,921 | $1,405,700 |
| 2025-12-03 | HOLLOWAY JEAN F | General Counsel | Sale | 7,315 | $331,370 |
| 2025-12-03 | MACKIN JAMES PATRICK | Chief Executive Officer | Option Exercise | 30,921 | $915,880 |
| 2025-12-02 | MACKIN JAMES PATRICK | Chief Executive Officer | Sale | 30,921 | $1,408,730 |
| 2025-12-02 | MACKIN JAMES PATRICK | Chief Executive Officer | Option Exercise | 30,921 | $915,880 |
| 2025-12-01 | HORTON AMY D | Officer | Gift | 750 | - |
| 2025-11-21 | STANTON MARSHALL S | Officer | Sale | 47,376 | $2,133,920 |
| 2025-11-21 | STANTON MARSHALL S | Officer | Option Exercise | 47,376 | $672,988 |
| 2025-11-20 | STANTON MARSHALL S | Officer | Sale | 15,276 | $674,825 |
| 2025-11-20 | STANTON MARSHALL S | Officer | Option Exercise | 3,388 | $52,434 |
| 2025-11-18 | HOFF ELIZABETH A. | Director | Sale | 4,200 | $189,412 |
| 2025-11-17 | HORTON AMY D | Officer | Sale | 6,000 | $274,380 |
| 2025-11-17 | HOLLOWAY JEAN F | General Counsel | Sale | 12,787 | $576,502 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
Canaccord Genuity
2025-11-07
Buy
Buy
Citizens
2025-11-07
Market Outperform
Market Outperform
Needham
2025-11-07
Buy
Buy
JMP Securities
2025-10-10
Market Outperform
Market Outperform
Stifel
2025-09-29
Buy
Buy
Canaccord Genuity
2025-09-29
Buy
Buy
Needham
2025-08-22
Buy
Buy
Ladenburg Thalmann
2025-08-13
Buy
Neutral
Canaccord Genuity
2025-08-08
Buy
Buy
JMP Securities
2025-08-08
Market Outperform
Market Outperform
Past News Coverage
Recent headlines mentioning AORT from our newsroom.
Newest → oldest
No matching news yet.